Phaseline

Companies › Vaneltix Pharma

Vaneltix Pharma: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Genitourinary.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VNX001
Combination of alkalinized lidocaine HCl and heparin sodium
–Phase 2Interstitial Cystitis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05737121VNX001Phase 2Interstitial CystitisGenitourinaryJun 2026
NCT06394830VNX001Phase 2Interstitial CystitisGenitourinaryJun 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Kira Pharmacenticals (US) Veloxis Pharmaceuticals Juro Sciences Vifor Fresenius Medical Care Renal Pharma Tioga Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.